SCHEMBL25868407

SCHEMBL25868407

CC(C)CCOCCOCCOCC(=O)OC(C)C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.57
KDM4E B2RXH2 2/20 0.45
HSD17B10 Q99714 2/20 0.45
ALDH1A1 P00352 2/20 0.45
LMNA P02545 2/20 0.36
MAPT P10636 2/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
TSHR P16473 2/20 0.34
CYP19A1 P11511 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
HTT P42858 1/20 0.32
PPARG P37231 1/20 0.32
NCOA2 Q15596 1/20 0.32
NCOA1 Q15788 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7651937 0.90 TDP1 (0.43) TDP1KDM4EHSD17B10ALDH1A1LMNA
SCHEMBL26199693 0.85 TDP1 (0.45) TDP1KDM4EHSD17B10ALDH1A1LMNA
SCHEMBL1401407 0.82 MEN1 (0.44) TDP1KDM4EHSD17B10ALDH1A1LMNA
SCHEMBL8862807 0.82 TDP1 (0.39) TDP1KDM4EHSD17B10ALDH1A1LMNA
SCHEMBL1401325 0.82 MEN1 (0.44) TDP1KDM4EHSD17B10ALDH1A1LMNA
SCHEMBL7651938 0.82 MAPT (0.40) TDP1KDM4EHSD17B10ALDH1A1LMNA
SCHEMBL22360502 0.82 TDP1 (0.39) TDP1KDM4EHSD17B10ALDH1A1LMNA
SCHEMBL16077020 0.82 TDP1 (0.46) TDP1KDM4EHSD17B10ALDH1A1LMNA
SCHEMBL13327035 0.82 TDP1 (0.54) TDP1KDM4EHSD17B10ALDH1A1LMNA
SCHEMBL17908770 0.81 LMNA (0.50) TDP1KDM4EHSD17B10ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240072809-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-02-29 US disclosed
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2023-11-21 US disclosed
US-20230233689-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins UNIV YALE (US) 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins ASGR1, ENGASE, FCGR2A TDP1 3930/4885KDM4E 4460/4885HSD17B10 3664/4885
US-20230233689-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins ASGR1, LDLR, FCGR2A TDP1 4559/4885KDM4E 4040/4885HSD17B10 3284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.